Mood-Stabiliz

Journal of Clinical Psychopharmacology

Volumn 38, Issue 1, 2018, Pages 7-10

  Patel, Neil ^a   Viguera, Adele C ^a,b   Baldessarini, Ross J ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

anticonvulsants; antiepileptics; bipolar disorder; folic acid; neural tube defects; pregnancy; spina bifida; teratogenic; valproate; women

Indexed keywords

CARBAMAZEPINE; FOLIC ACID; LAMOTRIGINE; VALPROIC ACID; ANTICONVULSIVE AGENT; TRANQUILIZER; TRIAZINE DERIVATIVE;

BIPOLAR DISORDER; CONTROLLED STUDY; DRUG APPROVAL; DRUG SAFETY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; OFF LABEL DRUG USE; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SPINAL DYSRAPHISM; TERATOGENICITY; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED; DIETARY SUPPLEMENT; NEURAL TUBE DEFECT; PREGNANCY COMPLICATION;

ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; HUMANS; NEURAL TUBE DEFECTS; PREGNANCY; PREGNANCY COMPLICATIONS; SPINAL DYSRAPHISM; TRIAZINES; VALPROIC ACID;

EID: 85040332641     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000813     Document Type: Review

References (36)

1. Baldessarini RJ. Chemotherapy in Psychiatry. 3rd ed. New York: Springer Press; 2013.
2. Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;11:CD010224.
3. Cunnington M, Tennis P. International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk ofmalformations in pregnancy. Neurology. 2005;64:955-960.
4. Hill DS, Wlodarczyk BJ, Palacios AM, et al. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother. 2010;10:943-959.
5. Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf. 2004;27:197-202.
6. Jablensky AV, Morgan V, Zubrick SR, et al. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry. 2005;162: 79-91.
7. Greene ND, Copp AJ. Neural tube defects. Annu Rev Neurosci. 2014;37: 221-242.
8. Copp AJ, Adzick NS, Chitty LS, et al. Spina bifida. Nat Rev Dis Primers. 2015;1:15007.
9. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl JMed. 1991;324:674-677.
10. Alsdorf R,Wyszynski DF. Teratogenicity of sodium valproate. Expert Opin Drug Saf. 2005;4:345-353.
11. Jentink J, Dolk H, LoaneMA, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ. 2010;341:c6581-c6588.
12. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10: 609-617.
13. Wlodarczyk BJ, Palacios AM, George TM, et al. Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A. 2012;158:2071-2090.
14. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl JMed. 2015;362: 2185-2193.
15. USPS (United States Preventive Services). US Preventive Services Task Force recommendation statement: folic acid supplementation for the prevention of neural tube defects. JAMA. 2017;317:183-189.
16. Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol. 2010;686:349-364.
17. Agopian AJ, Tinker SC, Lupo PJ, et al. Proportion of neural tube defects attributable to known risk factors. Birth Defects Res A Clin Mol Teratol. 2013;97:42-46.
18. Wilson RD, Audibert F, Brock JA, et al. Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies. J Obstet Gynaecol Can. 2015;37:534-552.
19. Mitchell LE, Adzick NS, Melchionne J, et al. Spina bifida. Lancet. 2004; 364:1885-1895.
20. Fathe K, Palacios AM, Finnell RH. Brief report novel mechanism for valproate-induced teratogenicity. Birth Defects Res A Clin Mol Teratol. 2014;100:592-597.
21. Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology. 1992;42(4 suppl 5):17-24.
22. De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, et al. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2015:CD007950.
23. Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects: implications for prevention. JAMA. 1995;274:1698-1702.
24. Viswanathan M, Treiman KA, Doto JK. Folic acid supplementation: evidence review for a US Preventive Services task force (Agency for Healthcare Research and Quality [ARHQ] Publication No. 14-05214-EF-1). US DHHS: Rockville, MD; 2017.
25. Mosley BS, Cleves MA, Siega-Riz AM, et al. Neural tube defects and maternal folate intake among pregnancies conceived after folic acid fortification in the United States. Am J Epidemiol. 2009;169:9-17.
26. Chitayat D, Matsui D, Amitai Y, et al. Folic acid supplementation for pregnant women and those planning pregnancy: 2015 update. J Clin Pharmacol. 2016;56:170-175.
27. NIH (National Institutes of Health). Folate: Dietary Supplement Fact Sheet, 20 April, 2016. Available at: https://ods. od. nih. gov/factsheets/Folate-HealthProfessional/. Accessed 28 March 2017. 27.
28. Nambisan M, Wyszynski DF, Holmes LB. No evidence of a protective effect due to periconceptional folic acid (PCFA) intake on risk for congenital anomalies in the offspring of mothers exposed to antiepileptic drugs (AEDs). Birth Defects Res. 2003;67:364.
29. Padmanabhan R, Shafiullah MM. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenit Anom (Kyoto). 2003;43: 29-40.
30. Harden CL, Pennell PB, Koppel BS, et al. Management issues for women with epilepsy-focus on pregnancy: vitamin K, folic acid, blood levels, and breast-feeding. Neurology. 2009;73:142-149.
31. Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2009;80:506-511.
32. Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol. 2009;28:1-10.
33. Jentink J, BakkerMK, NijenhuisCM, et al. Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid? Pharmacoepidemiol Drug Saf. 2010;19:803-807.
34. Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl JMed. 2011;364: 993-1004.
35. Saadai P, Wang A, Nout YS, et al. Human induced pluripotent stem cell-derived neural crest stem cells integrate into the injured spinal cord in the fetal lamb model of myelomeningocele. J Pediatr Surg. 2013;48: 158-163.
36. GoodwinGM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016; 30:495-553.